An advisory panel for the U.S. Food and Drug Administration voted 6-3 against AstraZeneca's oral dru...
AstraZeneca stock falls after FDA panel votes against new cancer drug
An advisory panel for the U.S. Food and Drug Administration voted 6-3 against AstraZeneca's oral drug camizestrant intended for a type of breast cancer...
Author: CNBC
Read Original Article